Degradation of B-Myb by ubiquitin-mediated proteolysis:: involvement of the Cdc34-SCFp45Skp2 pathway

被引:72
作者
Charrasse, S
Carena, I
Brondani, V
Klempnauer, KH
Ferrari, S
机构
[1] Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland
[2] Univ Munster, Inst Biochem, D-48149 Munster, Germany
关键词
B-Myb; ubiquitination; p45(Skp2); cyclin A;
D O I
10.1038/sj.onc.1203618
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
B-Myb, a highly conserved member of the Myb oncoprotein family, is a 110 kDa sequence-specific DNA binding protein expressed in virtually all proliferating cells, B-myb expression reaches its maximum at the G1/S phase boundary and during the S phase of the cell cycle. We have previously shown that B-Myb activity is cell cycle regulated and it is controlled by the antagonistic effects of cyclin Dt and A. Here we show that ectopic expression of cyclin A causes a pronounced reduction of B-Myb protein level, We provide evidence that in addition to triggering B-Myb activity an important effect of cyclin A is to facilitate multiple ubiquitination of B-Myb, The C-terminal domain of B-Myb is of key importance in mediating this effect of cyclin A, Contrary to full-length B-Myb, a C-terminal deletion mutant displays activity irrespective of cyclin A expression, does not undergo ubiquitination, and its half-life is not affected by cyclin A. Ectopic expression of either Cdc34 or the F-box protein p45(Skp2), respectively the E2 and E3 components of a ubiquitination pathway that regulates the G1/S transition, accelerates degradation of B-Myb, We show that B-Myb physically and functionally interacts with components of the Cdc34-SCFp45Skp2 ubiquitin pathway and propose that B-Myb degradation may be required for controlling the correct alternation of events during progression through the cell division cycle.
引用
收藏
页码:2986 / 2995
页数:10
相关论文
共 58 条
[1]   B-myb, a repressed trans-activating protein [J].
Ansieau, S ;
KowenzLeutz, E ;
Dechend, R ;
Leutz, A .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1997, 75 (11-12) :815-819
[2]  
ARSURA M, 1992, BLOOD, V79, P2708
[3]   Identification of cyclin A/Cdk2 phosphorylation sites in B-Myb [J].
Bartsch, O ;
Horstmann, S ;
Toprak, K ;
Klempnauer, KH ;
Ferrari, S .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 260 (02) :384-391
[4]  
Bartsch O, 1998, BIOLOGY OF TUMORS, P31
[5]   Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway [J].
Bies, J ;
Wolff, L .
ONCOGENE, 1997, 14 (02) :203-212
[6]   MOLECULAR-CLONING, EXPRESSION AND INVITRO FUNCTIONAL-CHARACTERIZATION OF MYB-RELATED PROTEINS IN XENOPUS [J].
BOUWMEESTER, T ;
GUEHMANN, S ;
ELBARADI, T ;
KALKBRENNER, F ;
VANWIJK, I ;
MOELLING, K ;
PIELER, T .
MECHANISMS OF DEVELOPMENT, 1992, 37 (1-2) :57-68
[7]   Regulation of E2F through ubiquitin-proteasome-dependent degradation: Stabilization by the pRB tumor suppressor protein [J].
Campanero, MR ;
Flemington, EK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2221-2226
[8]   A common human skin tumour is caused by activating mutations in β-catenin [J].
Chan, EF ;
Gat, U ;
McNiff, JM ;
Fuchs, E .
NATURE GENETICS, 1999, 21 (04) :410-413
[9]  
Charrasse S, 1999, CELL GROWTH DIFFER, V10, P611
[10]  
CURRAN T, 1984, CELL, V36, P259